source
- Pain drugmaker Latigo outlines plans to go publicThe Westlake-founded company specializes in non-opioid drugs that target sodium ion channels, and is now adding to what’s already been a busy month for the biotech IPO queue.BioPharma Dive · 10d ago↗ source
- ‘There is always a first’: Why US biotech Axiom will begin its IPO journey in Hong KongAxiom Biosciences intends to pursue an IPO on the Hong Kong Stock Exchange (HKEX), followed by a co-listing on the Nasdaq—a strategy the company claims is the first U.S. biotech to use.Fierce Biotech · 10d ago↗ source
- STAT+: The next step of site-neutral, and a fiery PBM hearingMedicare proposes to reduce payments to hospitals for certain drugs and imaging services.STAT · 10d ago↗ source